专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100256073A1 THERAPEUTIC AGENT COMPRISING LIPOCALIN 2 AGAINST CANCER METASTASIS, AND METHODS OF EARLY DIAGNOSIS AND INHIBITION OF CANCER METASTASIS USING LIPOCALIN 2 审中-公开
标题翻译：包含LOCOCALIN 2抗癌剂的治疗药物，以及早期诊断方法和使用LIPOCALIN 2抑制癌症METASTASIS
公开(公告)号：US20100256073A1
公开(公告)日：2010-10-07
申请号：US12779911
申请日：2010-05-13
申请人： Eun-kyoung Lee , Ho-jeong Lee , Kong-ju Lee , Jang-seong Kim , Doo-hong Park , Yeup Yoon , Hyun-jun Kim , In-hwan Lim
发明人： Eun-kyoung Lee , Ho-jeong Lee , Kong-ju Lee , Jang-seong Kim , Doo-hong Park , Yeup Yoon , Hyun-jun Kim , In-hwan Lim
IPC分类号： A61K38/16 , A61P35/00 , A61P35/04
CPC分类号： A61K38/1709 , A61K48/00 , C12N15/86 , C12N2740/15043
摘要： The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect.
摘要翻译：本发明涉及用于抑制癌症转移的药物组合物，更准确地说，涉及一种抗癌转移的新型药物组合物，其包含脂质运载蛋白2蛋白，编码该蛋白质的基因，含有表达载体转染的基因或表达载体的表达载体有效成分，使用该组合物抑制癌症转移的方法，用于预测癌症转移的诊断试剂盒，使用试剂盒选择转移风险组的方法，用于抑制癌症生长的新型药物组合物以及使用其抑制癌症生长的方法。本发明的药物组合物特异性地抑制癌症转移，从而可以显着地改善癌症治疗的效果。并且，使用该试剂盒的诊断试剂盒和选择转移风险组的方法能够通过测量肿瘤组织或体液中脂笼蛋白2的水平来选择转移风险组。因此，试剂盒和方法可以有助于癌症患者的有效临床控制。此外，本发明的组合物由于其肝癌生长抑制作用，可以有效地用于治疗肝癌。

2. 发明申请

US20090311224A1 THERAPEUTIC AGENT COMPRISING LIPOCALIN 2 AGAINST CANCER METASTASIS, AND METHODS OF EARLY DIAGNOSIS AND INHIBITION OF CANCER METASTASIS USING LIPOCALIN 2 审中-公开
标题翻译：包含LOCOCALIN 2抗癌剂的治疗药物，以及早期诊断方法和使用LIPOCALIN 2抑制癌症METASTASIS
公开(公告)号：US20090311224A1
公开(公告)日：2009-12-17
申请号：US11815088
申请日：2006-02-24
申请人： Eun-kyoung Lee , Ho-jeong Lee , Kong-ju Lee , Jang-seong Kim , Doo-bong Park , Yeup Yoon , Hyun-jun Kim , In-hwan Lim
发明人： Eun-kyoung Lee , Ho-jeong Lee , Kong-ju Lee , Jang-seong Kim , Doo-bong Park , Yeup Yoon , Hyun-jun Kim , In-hwan Lim
IPC分类号： A61K35/12 , C07H21/00 , C12N15/63 , C12N5/00 , A61K31/7052 , C07K14/00 , A61K38/16 , C07K16/00 , A61P35/00 , C12Q1/68
CPC分类号： A61K38/1709 , A61K48/00 , C12N15/86 , C12N2740/15043
摘要： The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect.
摘要翻译：本发明涉及用于抑制癌症转移的药物组合物，更准确地说，涉及一种抗癌转移的新型药物组合物，其包含脂质运载蛋白2蛋白，编码该蛋白质的基因，含有表达载体转染的基因或表达载体的表达载体有效成分，使用该组合物抑制癌症转移的方法，用于预测癌症转移的诊断试剂盒，使用试剂盒选择转移风险组的方法，用于抑制癌症生长的新型药物组合物以及使用其抑制癌症生长的方法。本发明的药物组合物特异性地抑制癌症转移，从而可以显着地改善癌症治疗的效果。并且，使用该试剂盒的诊断试剂盒和选择转移风险组的方法能够通过测量肿瘤组织或体液中脂笼蛋白2的水平来选择转移风险组。因此，试剂盒和方法可以有助于癌症患者的有效临床控制。此外，本发明的组合物由于其肝癌生长抑制作用，可以有效地用于治疗肝癌。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式